Aktis Oncology, Inc. (AKTS)
NasdaqGS · USD · Healthcare · Biotechnology
$16.11 (+2.42%) as of
Key statistics
- Market cap
- 896.03M
- Forward P/E
- -7.55
- EPS (TTM)
- -1.70
- Dividend yield
- 0.00%
- 52-week range
- 14.72 – 34.19
- Revenue (TTM)
- 10.06M
- Profit margin
- 0.00%
- Analyst target
- $35.88
- Volume
- 40.33k
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 79
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.